BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 17876272)

  • 21. Non-total body irradiation containing preparative regimen in alternative donor bone marrow transplantation for severe aplastic anemia.
    Lee JH; Choi SJ; Lee JH; Lee YS; Seol M; Ryu SG; Lee JS; Kim WK; Lee KH
    Bone Marrow Transplant; 2005 Apr; 35(8):755-61. PubMed ID: 15735661
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Partially matched related donor peripheral blood progenitor cell transplantation in paediatric patients adding fludarabine and anti-lymphocyte gamma-globulin.
    Ortín M; Raj R; Kinning E; Williams M; Darbyshire PJ
    Bone Marrow Transplant; 2002 Sep; 30(6):359-66. PubMed ID: 12235520
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
    Huisman C; Meijer E; Petersen EJ; Lokhorst HM; Verdonck LF
    Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation.
    Ayuk F; Diyachenko G; Zabelina T; Wolschke C; Fehse B; Bacher U; Erttmann R; Kröger N; Zander AR
    Biol Blood Marrow Transplant; 2008 Aug; 14(8):913-9. PubMed ID: 18640575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma.
    Hentschke P; Barkholt L; Uzunel M; Mattsson J; Wersäll P; Pisa P; Martola J; Albiin N; Wernerson A; Söderberg M; Remberger M; Thörne A; Ringdén O
    Bone Marrow Transplant; 2003 Feb; 31(4):253-61. PubMed ID: 12621459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allogeneic stem cell transplantation in patients with Fanconi's anemia and myelodysplasia or leukemia utilizing low-dose cyclophosphamide and total body irradiation.
    Ayas M; Al-Jefri A; Al-Mahr M; Rifai S; Moussa E; Karaoui M; Roberts G; El-Solh H
    Bone Marrow Transplant; 2004 Jan; 33(1):15-7. PubMed ID: 14578932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of acute graft-versus-host disease following reduced-intensity stem-cell transplantation from an HLA-identical related donor.
    Murashige N; Kami M; Mori S; Katayama Y; Kobayashi K; Onishi Y; Hori A; Kishi Y; Hamaki T; Tajima K; Kanda Y; Tanosaki R; Takaue Y
    Am J Hematol; 2008 Aug; 83(8):630-4. PubMed ID: 18454459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 400 cGy TBI with fludarabine for reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation.
    Sobecks RM; Dean R; Rybicki LA; Chan J; Theil KS; Macklis R; Andresen S; Kalaycio M; Pohlman B; Ferraro C; Cherni K; Sweetenham J; Copelan E; Bolwell BJ
    Bone Marrow Transplant; 2008 Dec; 42(11):715-22. PubMed ID: 18711346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
    Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
    Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unrelated umbilical cord blood transplantation for adults with haematological malignancies: results from a single Australian centre.
    Bradstock KF; Hertzberg MS; Kerridge IH; Svennilson J; McGurgan M; Huang G; Antonenas V; Gottlieb DJ
    Intern Med J; 2006 Jun; 36(6):355-61. PubMed ID: 16732860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protective conditioning for acute graft-versus-host disease.
    Lowsky R; Takahashi T; Liu YP; Dejbakhsh-Jones S; Grumet FC; Shizuru JA; Laport GG; Stockerl-Goldstein KE; Johnston LJ; Hoppe RT; Bloch DA; Blume KG; Negrin RS; Strober S
    N Engl J Med; 2005 Sep; 353(13):1321-31. PubMed ID: 16192477
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
    Ayuk F; Diyachenko G; Zabelina T; Panse J; Wolschke C; Eiermann T; Binder T; Fehse B; Erttmann R; Kabisch H; Bacher U; Kröger N; Zander AR
    Exp Hematol; 2008 Aug; 36(8):1047-54. PubMed ID: 18456390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.
    Bacigalupo A; Lamparelli T; Barisione G; Bruzzi P; Guidi S; Alessandrino PE; di Bartolomeo P; Oneto R; Bruno B; Sacchi N; van Lint MT; Bosi A;
    Biol Blood Marrow Transplant; 2006 May; 12(5):560-5. PubMed ID: 16635791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unrelated umbilical cord blood transplantation using a TBI/FLAG conditioning regimen for adults with hematologic malignancies.
    Okada M; Fujimori Y; Misawa M; Kai S; Nakajima T; Okikawa Y; Satake A; Itoi H; Takatsuka H; Itsukuma T; Nishioka K; Tamaki H; Ikegame K; Hara H; Ogawa H
    Biol Blood Marrow Transplant; 2008 Aug; 14(8):896-903. PubMed ID: 18640573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation.
    Ayuk F; Perez-Simon JA; Shimoni A; Sureda A; Zabelina T; Schwerdtfeger R; Martino R; Sayer HG; Alegre A; Lahuerta JJ; Atanackovic D; Wolschke C; Nagler A; Zander AR; San Miguel JF; Kröger N
    Haematologica; 2008 Sep; 93(9):1343-50. PubMed ID: 18641030
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose-dependent effects of in vivo antithymocyte globulin during conditioning for allogeneic bone marrow transplantation from unrelated donors in patients with chronic phase CML.
    Schleuning M; Günther W; Tischer J; Ledderose G; Kolb HJ
    Bone Marrow Transplant; 2003 Aug; 32(3):243-50. PubMed ID: 12858194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
    Heinzelmann F; Lang PJ; Ottinger H; Faul C; Bethge W; Handgretinger R; Bamberg M; Belka C
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):523-8. PubMed ID: 17869449
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fludarabine, low-dose busulfan and antithymocyte globulin as conditioning for Fanconi anemia patients receiving bone marrow transplantation from HLA-compatible related donors.
    Maschan AA; Trakhtman PE; Balashov DN; Shipicina IP; Skorobogatova EV; Skvortsova YV; Dyshlevaja ZM; Samochatova EV; Rumiantsev AG
    Bone Marrow Transplant; 2004 Aug; 34(4):305-7. PubMed ID: 15195080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for congenital sideroblastic anemia.
    Medeiros BC; Kolhouse JF; Cagnoni PJ; Ryder J; Nieto Y; Rabinovitch R; Shpall EJ; Bearman SI; Jones RB; McSweeney PA
    Bone Marrow Transplant; 2003 Jun; 31(11):1053-5. PubMed ID: 12774059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.